Merrimack Pharmaceuticals Inc (MACK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2013 | 12-2012 | 12-2011 | 12-2010 | 12-2009 | |
| Sales | 47,786 | 48,921 | 34,215 | 20,305 | 2,148 |
| Gross Profit | 47,786 | 48,921 | 34,215 | 20,305 | 2,148 |
| Operating Expenses | 168,326 | 141,663 | 115,084 | 69,481 | 49,836 |
| Operating Income | -120,540 | -92,742 | -80,869 | -49,176 | -47,688 |
| Interest Expense | 10,938 | 553 | 13 | 3,726 | 4,909 |
| Other Income | 793 | 1,541 | 1,206 | 2,743 | 122 |
| Pre-tax Income | -130,685 | -91,754 | -79,676 | -50,159 | -52,475 |
| Income Tax | N/A | N/A | N/A | N/A | -3,402 |
| Net Income Continuous | -130,685 | -91,754 | -79,676 | -50,159 | -49,073 |
| Minority Interests | 240 | -477 | -453 | -55 | N/A |
| Net Income | $-130,925 | $-91,277 | $-79,223 | $-50,104 | $-49,073 |
| EPS Basic Total Ops | -13.20 | -12.80 | -76.70 | -55.70 | -72.80 |
| EPS Basic Continuous Ops | -13.21 | -12.60 | -70.24 | -45.62 | -66.43 |
| EPS Diluted Total Ops | -13.20 | -12.80 | -76.70 | -55.70 | -72.80 |
| EPS Diluted Continuous Ops | -13.21 | -12.60 | -70.24 | -45.62 | -66.43 |
| EBITDA(a) | $-117,951 | $-89,078 | $-76,273 | $-45,548 | $-45,250 |